



# Crystalloid coloadng vs. colloid coloadng in elective Caesarean section: postspinal hypotension and vasopressor consumption, a prospective, observational clinical trial

Lutz Kaufner<sup>1</sup> · A. Karekla<sup>2</sup> · A. Henkelmann<sup>1</sup> · S. Welfle<sup>2</sup> · K. von Weizsäcker<sup>3</sup> · L. Hellmeyer<sup>4</sup> · C. von Heymann<sup>1,2</sup>

Received: 17 July 2018 / Accepted: 6 November 2018 / Published online: 6 December 2018  
© Japanese Society of Anesthesiologists 2018

## Abstract

**Background** Maternal hypotension is a common side effect of spinal anaesthesia for Caesarean section. The combination of colloid coloadng and vasopressors was considered our standard for its prevention and treatment. As the safety of hydroxyethyl starch is under debate, we replaced colloid with crystalloid coloadng.

**Objective** We hypothesize that the mean blood pressure drop is greater when coloadng with crystalloids.

**Design** Prospective, observational clinical trial.

**Setting** Two-centre study conducted in Berlin, Germany.

**Patients** Parturients scheduled for a Caesarean section were screened for eligibility.

**Intervention** The study protocol and patient monitoring were based on the standard operating procedure for Caesarean section in both centres. The data from the crystalloid group were prospectively collected between November 2014 and July 2015.

**Main outcome measures** The primary endpoint was the median drop in mean blood pressure after induction of spinal anaesthesia. Secondary endpoints were incidence of hypotension (drop > 20% of baseline systolic pressure / drop < 100 mmHg), vasopressor and additional fluid requirements (mL), incidence of bradycardia (heart rate < 60 beats per minute), blood loss, Apgar score, and umbilical artery pH. In case of hypotension, patients received phenylephrine or cafedrine/theodrenaline according to their heart rate. A  $p < 0.05$  was considered significant.

**Results** 345 prospectively enrolled patients ( $n = 193$  crystalloid group vs.  $n = 152$  colloid group) were analysed. The median drop in mean blood pressure was greater in the crystalloid group [34 mmHg (25; 42 mmHg) vs. 21 mmHg (13; 29 mmHg),  $p < 0.001$ ]. Incidences of hypotension [93.3% vs. 83.6%,  $p: 0.004$ ] and bradycardia [19.7% vs. 9.9%,  $p: 0.012$ ] were also significantly greater in the crystalloid group. Vasopressor requirements, blood loss and neonatal outcome were not different between the groups.

**Conclusions** Crystalloid coloadng was associated with a greater drop in mean blood pressure and a higher incidence of hypotension when compared with colloid coloadng. Neonatal outcome was, however, unaffected by the type of fluid.

**Trial registration** DRKS00006783 (<http://www.drks.de>).

**Keywords** Caesarean section · Spinal anaesthesia · Hypotension · Coloadng · Crystalloids · Colloids

---

Data for this study were presented as e-poster presentation at the German Anesthesiology Congress (DAC), 14–16 April 2016, Leipzig, Germany.

---

Lutz Kaufner and A. Karekla contributed equally.

---

✉ Lutz Kaufner  
lutz.kaufner@charite.de

Extended author information available on the last page of the article

## Introduction

Spinal anaesthesia (SpA) is considered to be the gold standard for elective Caesarean section (C/S) [1, 2]. The “Spinal Anaesthesia Induced Hypotension” (SAIH) is the most common adverse effect, with an incidence up to 70% [3]. Remaining untreated, SAIH may be associated with significant risks for mother and newborn [4, 5]. Most commonly, SAIH is defined as the decrease of the systolic blood pressure ( $BP_{\text{syst}}$ ) by > 20% from baseline or a drop in  $BP_{\text{syst}}$  below 100 mmHg [6]. The lack of an internationally

accepted definition of SAIH hampers the comparability of study results [7]. Furthermore, the  $BP_{\text{sys}}$  when compared to mean blood pressure ( $BP_{\text{mean}}$ ) seems to correlate less with the organ perfusion [4].

SpA induces a reversible sympathetic block which leads to a drop in systemic vascular resistance and redistribution of blood volume to the lower extremities due to a loss of arteriolar tone [4, 8, 9]. A decrease in uteroplacental blood flow could influence the foetal circulation [10], leading to an increased risk of foetal acidosis [11]. Replacement of intravascular volume and vasopressors are considered the gold standard for prevention and treatment of SAIH [12, 13]. A multicentre study in 2014 showed a reassuring use of third-generation HES in the obstetric setting and provided maternal and neonatal peripartum safety data [18]. Furthermore, a recent meta-analysis showed that colloid compared with crystalloid loading significantly reduced the incidence of SAIH [3]. Most of the RCT showed a higher incidence of hypotension when using a crystalloid preloading, but did not report results regarding the vasopressor consumption and neonatal outcome. Previous studies have shown crystalloid preloading to be inferior to colloid preloading in the prevention of SAIH, probably due to the rapid redistribution of the infused crystalloid volume [19]. Until now there is only one controlled study left that compares a colloid- with a crystalloid-based coloadng regime in combination with phenylephrine infusion to maintain the baseline  $BP_{\text{sys}}$  in elective C/S [21]. Due to the recent debate on the safety of hydroxyethyl starch (HES) and the impact on renal function [14, 15] in intensive care patients and the decision of European and national authorities [16] to restrict the use of HES solutions for hypovolemia caused by acute blood loss only [17], we changed our standard volume replacement technique for elective C/S from HES-based coloadng to crystalloid-based coloadng. Therefore, we conducted a trial hypothesizing that the technique of crystalloid coloadng compared to colloid coloadng is associated with a greater drop of mean of BP ( $\Delta BP_{\text{mean}}$ ), a higher incidence of hypotension, and an increased vasopressor consumption. Furthermore, we aimed to identify risk factors for SAIH when coloadng with a crystalloid.

## Methods

This two-centre, prospective, observational clinical trial (German Registry for Prospective Clinical Studies, DRKS00006783) was conducted at the Departments of Anaesthesiology of the Charité-Universitätsmedizin Berlin and the Vivantes Klinikum im Friedrichshain Berlin, Germany. After the Ethical Committee of Charité-Universitätsmedizin Berlin, Germany (EA1/240/14, Chairperson Prof. Dr. med. R. Uebelhack) approved the trial at both

hospitals on 29.09.2014, women scheduled for elective C/S became eligible for inclusion. Written informed consent was obtained from each woman at least 24 h before surgery.

Women were enrolled if they were of age, mentally healthy, American Society of Anaesthesiologists (ASA) physical status Class I–II and scheduled to undergo elective C/S under neuraxial anaesthesia. Exclusion criteria were age < 18, decline of informed consent for spinal anaesthesia, limited ability to understand German, premature birth < 28 weeks of gestation or stillbirth, psychiatric condition or medication, alcohol abuse, chronic or any pregnancy-induced hypertensive disease, HELLP-syndrome, allergies to local anaesthetics and opioids, haemostatic disorders, or any other contraindications for spinal anaesthesia. Patients who required additional anaesthesia/analgesia (epidural top up bolus or general anaesthesia) outside of the defined protocol and patients who delivered after working hours (4 pm) were also excluded from the study.

The study protocol and monitoring of the patients were based on the standard operating procedure (SOP) for C/S in both centres. Coloadng with a HES-based fluid was the standard treatment at both institutions until September 2013 and was replaced by a crystalloid-based regimen thereafter. The data from 152 ASA I–II patients treated with colloid coloadng who were consecutively enrolled for an earlier prospective randomized study [20] were compared with 193 patients consecutively enrolled and subsequently treated with crystalloid coloadng. The data from the crystalloid group were prospectively collected between November 2014 and July 2015 and identical inclusion and exclusion criteria were applied.

The standard monitoring, consisting of non-invasive blood pressure measured every minute, heart rate, ECG, and pulse oximetry were applied, followed by the validation of the baseline  $BP_{\text{mean}}$  (the median of three measurements). We defined the measurement of lowest mean blood pressure until completion of spinal anaesthesia and before skin incision. Patients included in this study did not receive any other intravenous fluids prior to coloadng. The preoperative fasting time was as recommended by the European Society of Anaesthesiology: 2 h for clear fluids and 6 h for solids. Coloadng with 1000 mL balanced HES 130/0.4 (Volulyte®, Fresenius-Kabi, Bad Homburg, Germany) or 1000 mL balanced crystalloid solution (Sterofundin Iso®, B.Braun, Melsungen, Germany) was then started through an 18G intravenous cannula using a pressure bag, at the induction of spinal anaesthesia and was completed within 15 min. After coloadng, women in both groups received a baseline infusion of 500 mL crystalloid solution until the end of surgery. In case of SIAH, vasopressors were the first-line therapy without giving any additional crystalloid or colloid solution. SpA followed a standardized protocol and was performed by an anaesthetist under standard monitoring and

cardiotocography in a sitting position. After local anaesthesia of the skin with lidocaine 1%, a 27G or 25G pencil point needle was inserted (either as a single shot or combined spinal epidural, in the majority of cases at the lumbar vertebrae level 3–4) until the intrathecal space was identified. Patients were placed on a 30° left-tilted supine position. The sensory level of anaesthesia was tested using loss of cold sensation. A bilateral sensory block height at T6 was required to commence surgery. The dosage of bupivacaine applied related to the patients' height as follows:

< 160 cm:	8 mg of isobaric bupivacaine + 5 µg sufentanil
160–180 cm:	9 mg of isobaric bupivacaine + 5 µg sufentanil
> 180 cm:	10 mg of isobaric bupivacaine + 5 µg sufentanil

Hypotension was defined as a  $BP_{syst} < 100$  mmHg or a drop of  $BP_{syst} > 20\%$  of baseline. This drop was treated with fractionated boluses of 1 mL (0.1 mg) phenylephrine if the heart rate was  $\geq 60$  beats per minute or with 1 mL cafedrine/theodrenaline (20 mg cafedrine and 1 mg theodrenaline) if the heart rate was  $< 60$  beats per minute. After umbilical cord clamping, 3 IU of oxytocin were given slowly intravenously, and an infusion of 20 IU oxytocin/500 mL balanced crystalloid at a rate of 63 mL/h was started if necessary. Only after delivery 4 mg ondansetron or 1 mg granisetron was applied in case of nausea.

Data were collected using a case report form (CRF) and statistical analysis was performed with SPSS® Version 23.0. For the calculation of the number of patients, we used the  $BP_{mean}$  difference of 26.435 mmHg and the standard deviation of  $\pm 12.918$  mmHg from a patient collective of our clinic. Assuming a 10%  $BP_{mean}$  difference and a power of 80%, we needed to recruit 190 patients (nQuery Advisor® Release 7.0, Stat. Solutions Ltd. & South Bank, Crosse's Green, Cork, Ireland).

The primary endpoint was the difference between baseline  $BP_{mean}$  and lowest  $BP_{mean}$  measurements documented from the onset of spinal anaesthesia until the end of surgery ( $\Delta BP_{mean}$ ). Secondary endpoints were incidence of hypotension, vasopressor consumption (mL), additional intraoperative fluid requirements (mL), incidence of bradycardia (heart rate  $< 60$  beats per minute), estimated blood loss (mL), Apgar score, and the umbilical artery pH.

After assessing the normality of the data distributions, the data were expressed as the mean  $\pm$  standard deviation, median (25% percentile, 75% percentile), or frequency (percentage). Differences between groups were tested with parametric (Student's *t* test) and non-parametric tests (Mann–Whitney *U* test) for independent variables. Frequencies were tested with Chi-square test.

We also looked at possible risk factors for a  $\Delta BP_{mean} > 25\%$ ; furthermore, we assessed the correlation co-efficient for  $BMI/\Delta BP_{mean}$  and baseline  $BP_{mean}/\Delta BP_{mean}$ .

Two-tailed *p* values  $< 0.05$  were considered statistically significant.

## Results


In the crystalloid group, 346 women were screened for eligibility, 262 were enrolled in the study. 204 women received the protocol treatment after 58 women were subsequently excluded due to withdrawal of consent, spontaneous birth, delivery in another hospital, or Caesarean section after 4 pm. Eleven patients needed supplemental treatment (either epidural top up bolus or general anaesthesia) and were, therefore, excluded from the study. Data from 193 patients from the crystalloid group were included in the final analysis. From the colloid group, 179 patients were screened, 27 received additional treatment and were excluded. In the colloid group, 152 patient data that met the inclusion criteria were included in the final analysis (Fig. 1).

With the exception of baseline  $BP_{mean}$ , demographic patient characteristics such as age, BMI (body mass index), gravidity, parity, and ASA classification did not significantly differ between the groups. Baseline  $BP_{mean}$  was significantly higher in the crystalloid group compared to the colloid group (Table 1).

The  $\Delta BP_{mean}$  showed a significantly greater drop in the crystalloid compared to the colloid group (Fig. 2). The incidence of hypotension in the crystalloid group was significantly higher than in the colloid group (Table 2). Vasopressor requirements were inhomogeneous between the groups. Significantly more phenylephrine was administered in the colloid group, while cafedrine/theodrenaline consumption was significantly greater in the crystalloid group. The total amount of required vasopressors was not significantly different between the groups (Fig. 3). Intraoperative requirements of additional intravenous fluids were significantly greater in the crystalloid group (Table 2). The incidence of bradycardia differed between crystalloid and colloid groups significantly with the incidence in the crystalloid group being greater compared to that in the colloid group (Table 2). No differences regarding perioperative blood loss were observed (Table 2).

Neonatal outcomes such as umbilical pH and Apgar score did not differ significantly between the groups (Table 3). BMI, baseline  $BP_{mean}$ , crystalloid coload and administration interspace were significantly different in the groups of  $\Delta BP_{mean} \leq 25\%$  and  $\Delta BP_{mean} > 25\%$  (Table 4). The sensory block spread was significantly related to the incidence of bradycardia (Table 5).

**Fig. 1** Flowchart of study population



**Table 1** Maternal characteristics and baseline data

Maternal characteristics and baseline data	Crystalloid group (n = 193)	Colloid group (n = 152)	p value
Age (years)	33 (28;36)	32 (27;36)	0.149 <sup>S</sup>
BMI (kg/m <sup>2</sup> )	28 (25;32)	28 (25;32)	0.531 <sup>S</sup>
ASA, n (%)			0.440 <sup>SSS</sup>
I	190 (98.4%)	151 (99.3%)	
II	3 (1.6%)	1 (0.7%)	
Gemini	6 (3.1%)	10 (6.6%)	0.128 <sup>SSS</sup>
Gravidity (n)	2 (1;3)	2 (1;3)	0.237 <sup>S</sup>
Parity (n)	1 (0;1)	1 (0;1)	0.980 <sup>S</sup>
Gestational week, n (%)			0.427 <sup>SSS</sup>
32–37	28 (14.5%)	26 (17.1%)	
38–41	165 (85.5%)	121 (79.6%)	
Missing		5 (3.3%)	
Baseline BP <sub>mean</sub> (before co-loading/SpA) (mmHg)	95.97 ± 10.57	92.94 ± 10.77	0.009 <sup>SS</sup>


BMI body mass index, ASA American Society of Anesthesiologists Classification, BP<sub>mean</sub> mean blood pressure, SpA spinal anaesthesia

<sup>S</sup>Mann–Whitney U test

<sup>SS</sup>Student’s t test

<sup>SSS</sup>χ<sup>2</sup> test

A significant positive correlation was found for BMI and ΔBP<sub>mean</sub>, as well as for baseline BP<sub>mean</sub> and ΔBP<sub>mean</sub> (Figs. 4, 5).



**Fig. 2** ΔBP<sub>mean</sub> crystalloid vs. colloid group. ΔBP<sub>mean</sub> drop of systolic blood pressure

## Discussion

The main result of the investigation is that crystalloid compared to colloid coloadng for elective C/S is associated with a greater ΔBP<sub>mean</sub> and a higher incidence of SAIH. The total amount of vasopressors and blood loss showed no significant differences between the groups. In terms of neonatal outcome, the combination of crystalloid coloadng and vasopressors was not found to be inferior to the combination of colloid coloadng and vasopressors.

A meta-analysis published by Ripolles et al. compared 11 RCTs, ten of which used a preload and only one a coloadng regime as volume replacement technique for SpA in C/S women. The authors concluded that the use

**Table 2** Outcome data


Outcome data	Crystalloid group (n = 193)	Colloid group (n = 152)	p value
Sensory level at CS beginning, n (%)			0.080 <sup>SSS</sup>
T2–4	66 (34.2%)	66 (43.4%)	
T5–6	127 (65.8%)	86 (56.6%)	
Time of local anaesthetic injection- maximum BP <sub>mean</sub> drop (min)	10 (4;21)	9 (5;15)	0.444 <sup>S</sup>
Hypotension after SpA, n (%)	180 (93.3%)	127 (83.6%)	0.004 <sup>SSS</sup>
Lowest BP <sub>mean</sub> after SpA (mmHg)	61.82 ± 10.58	71.50 ± 9.93	< 0.001 <sup>SS</sup>
Pulse pressure (mmHg)	43 (34;51.5)	40 (36;48.75)	0.213 <sup>S</sup>
Bradycardia after SpA, n (%)	38 (19.7%)	15 (9.9%)	0.012 <sup>SSS</sup>
Estimated blood loss, n (%)			0.108 <sup>SSS</sup>
Up to 500 mL	170 (88.1%)	121 (79.6%)	
501–1000 mL	21 (10.9%)	29 (19.1%)	
1001–1500 mL	2 (1.0%)	1 (0.7%)	
1501–2000 mL	0 (0%)	1 (0.7%)	
Addition to 1000 mL coload intra- operative crystalloid requirements (mL)	600 (500;800)	500 (500;750)	0.001 <sup>S</sup>

T thoracic vertebrae, BP<sub>mean</sub> mean blood pressure, SpA spinal anaesthesia

<sup>S</sup>Mann–Whitney U test

<sup>SS</sup>Student's t test

<sup>SSS</sup> $\chi^2$  test

**Fig. 3** Vasopressor consumption crystalloid versus colloid group

of colloid compared to crystalloid loading was associated with a significantly lower incidence of SAIH [3]. Different definitions of SAIH and a lack of differentiation between pre- and coload regimens in this review, however, created a trend in favour of colloid coload. Only McDonald et al. [21] compared a colloid- (6% w/v hydroxyethyl starch solution) with a crystalloid-based (Hartmann) coload regimens in combination with phenylephrine infusion to maintain the baseline BP<sub>sys</sub> in elective C/S. After double-blind randomization, the groups consisted

of 60 parturients; phenylephrine infusion (0.5 mg/mL) as well as a rescue bolus application (0.1 mg/mL) were titrated to maintain maternal baseline BP<sub>mean</sub>. No significant differences in the cardiac output, the vasopressor consumption and hemodynamic stability of the two groups were observed. The authors concluded that, with regard to the missing benefit of a colloid coload and the higher risk profile of colloids, a crystalloid coload combined with phenylephrine infusion and a rescue bolus application appears to be an equally effective strategy in treating SAIH [21]. Our data point to a greater  $\Delta$ BP<sub>mean</sub> and a greater incidence of hypotension using crystalloid coload which may be related to our bolus application of vasopressors without an early phenylephrine infusion at the beginning of SpA.

The effectiveness of crystalloid preloading as a hydration technique for SpA in C/S has been questioned in recent years and is no longer recommended [13, 19, 22–24]. When preloading, a rapid crystalloid redistribution was observed indicating that only a small amount of the crystalloid fluid remains in the intravascular space at the time of maximum vasodilatation following SpA [24, 25]. Ueyama et al. showed that 30 min after preloading with 1.5 L of fluid, only 28% of crystalloid vs. 100% of colloid fluids remained in the circulation [25]. Based on fluid volume kinetics described by Ewaldsson et al., the rapid administration of intravenous fluids just after the induction of SpA would be the best way to prevent a BP drop [26]. In conclusion, the shorter intravascular volume expansion of crystalloid fluids may be the

**Table 3** Neonatal outcome

Neonatal outcome data	Crystalloid group (n = 193)	Colloid group (n = 152)	p value
Gender, n (%)			0.964 <sup>sss</sup>
Male	99 (51.3%)	78 (51.3%)	
Female	93 (48.2%)	74 (48.7%)	
Missing	1 (0.5%)	0	
Weight (g)	3319.90 ± 552.32	3215.79 ± 569.29	0.089 <sup>ss</sup>
Uterine incision-delivery time (min)	1 (1;2)	1 (1;2)	0.220 <sup>s</sup>
Umbilical artery pH	7.29 (7.25;7.32)	7.28 (7.26;7.30)	0.963 <sup>s</sup>
Apgar score 1 min, n (%)			0.747 <sup>sss</sup>
0–3	2 (1.0%)	2 (1.3%)	
4–6	3 (1.6%)	4 (2.7%)	
7–10	186 (96.4%)	143 (94.0%)	
Missing	2 (1.0%)	3 (2.0%)	
Apgar score 5 min, n (%)			0.666 <sup>sss</sup>
0–3	1 (0.5%)	0	
4–6	1 (0.5%)	1 (0.7%)	
7–10	189 (98.0%)	148 (97.3%)	
Missing	2 (1.0%)	3 (2.0%)	
Apgar score 10 min, n (%)			0.255 <sup>sss</sup>
0–3	0	0	
4–6	0	1 (0.7%)	
7–10	191 (99.0%)	148 (97.3%)	
Missing	2 (1.0%)	3 (2.0%)	

<sup>s</sup>Mann–Whitney *U* test<sup>ss</sup>Student's *t* test<sup>sss</sup> $\chi^2$  test

cause of their inferior effectiveness compared to colloid fluids used in coloadng.

To maintain BP<sub>syst</sub> and BP<sub>mean</sub> and secure neonatal outcome, fluid coloadng is often combined with vasopressors. Phenylephrine, due to its direct  $\alpha_1$ -receptor agonist activity, increases the systemic vascular resistance, has a lower placental transfer and is associated with a higher umbilical artery pH when compared with ephedrine [26–28]. Phenylephrine is often used as an infusion to prevent delayed SAIH [29] although an adequate bolus could also be sufficient [4]. Nevertheless, hypotension and reflex bradycardia were observed more often than an associated negative neonatal outcome [29, 30] indicating that at least in some cases, neonatal outcome seems to be unaffected by maternal hypotension. A recent study from Ngan Kee et al. randomized 214 patients into two groups, one receiving computer-controlled continuous infusion or intermittent boluses of phenylephrine in women receiving SpA for elective C/S. The results showed a more precise control of BP when using intermittent boluses with a lower total dose of phenylephrine; however, the differences between the groups were small and not clinically relevant [31].

Cafedrine/theodrenaline (Akrinor<sup>®</sup>) shows a positive inotropic and chronotropic activity with an almost unchanged

vascular resistance, mainly due to its  $\beta_2$ -receptor stimulation and mobilization of blood resources from the venous capacity system [32]. Cafedrine/theodrenaline in a ratio of 20:1 has been widely used as a vasopressor in Germany since its approval in 1963 [33]. Its safety has also been confirmed in women receiving C/S under SpA [32, 34, 35]. Although most of the existing data were obtained from animal studies [36], a retrospective analysis from Clemens et al. showed that the effectiveness of Akrinor<sup>®</sup> in restoring maternal BP in cases of SAIH had no effect on maternal heart rate, the Apgar score of the newborn, or umbilical pH [35]. The use of cafedrine/theodrenaline in cases of a reduced heart rate < 60/min and phenylephrine when the heart rate was  $\geq$  60 beats/min seems to be an effective therapeutic approach in the treatment of SAIH in our study.

Reflex bradycardia after phenylephrine application may occur due to a decrease in  $\beta$ -mimetic activity. The increased incidence of bradycardia in the crystalloid group is most likely associated with the more pronounced volume deficit after the onset of SpA, causing a reflex bradycardia [37] and resulting in a greater cafedrine/theodrenaline consumption in the crystalloid group. Known risk factors for bradycardia are age, sensory block  $\geq$  T4 [38], as well as the intrathecal injection of morphine [39]. Our results also indicate that the

**Table 4** Risk factors for  $\Delta BP_{\text{mean}} > 25\%$ 

Risk factors	$\Delta BP_{\text{mean}} \leq 25\%$ (n = 125)	$\Delta BP_{\text{mean}} > 25\%$ (n = 220)	p value
Age (years)	32 (27;36)	32 (28;36)	0.381 <sup>§</sup>
BMI (kg/m <sup>2</sup> )	28 (25;32)	29 (26;33)	0.042 <sup>§</sup>
Parity (n)	1 (0;1)	1 (0;1)	0.446 <sup>§</sup>
Gravidity (n)	2 (1;3)	2 (1;3)	0.530 <sup>§</sup>
Gestational week n (%)			0.477 <sup>§§§</sup>
Missing	1 (0.8%)	4 (1.8%)	
32–37	22 (17.6%)	32 (14.6%)	
38–41	102 (81.6%)	184 (83.6%)	
Baseline BP <sub>mean</sub> (mmHg)	88.91 ± 10.57	97.89 ± 9.43	< 0.001 <sup>§§</sup>
1000 mL coload, n (%)			< 0.001 <sup>§§§</sup>
Crystalloid	36 (28.8%)	157 (71.4%)	
Colloid	89 (71.2%)	63 (28.6%)	
Administration interspace n, (%)			0.011 <sup>§§§</sup>
L2–3	8.8%(11)	10.5%(23)	
L3–4	79.2%(99)	85.9%(189)	
L4–5	12.0%(15)	3.6%(8)	
Bradycardia	10.4%(13)	18.2%(40)	0.054 <sup>§§§</sup>
Sensory level at C/S beginning n, (%)			0.465 <sup>§§§</sup>
T2–4	51 (40.8%)	81 (36.8%)	
T5–6	74 (59.2%)	139 (63.2%)	
Estimated blood loss n, (%)			0.620 <sup>§§§</sup>
<500 mL	105 (84.0%)	186 (84.5%)	
501–1000 mL	18 (14.4%)	32 (14.5%)	
1001–1500 mL	1 (0.8%)	2 (0.9%)	
1501–2000 mL	1 (0.8%)	0	
Neonatal weight (g)	3215 ± 465	3307 ± 607	0.142 <sup>§§</sup>

$\Delta BP_{\text{mean}}$  drop of systolic blood pressure, *BMI* body mass index, *L* lumbar vertebrae, *T* thoracic vertebrae

<sup>§</sup>Mann–Whitney *U* test

<sup>§§</sup>Student's *t* test

<sup>§§§</sup> $\chi^2$  test


**Table 5** Risk factors for bradycardia

Risk factors for bradycardia	Bradycardia (n = 53)	No bradycardia (n = 292)	p value
Sensory block %, (n)			< 0.001 <sup>§§§</sup>
T2–4	32 (60.4%)	100 (34.2%)	
T5–6	21 (39.6%)	192 (65.8%)	
Age	33 (28;37)	32 (28;36)	0.351 <sup>§</sup>
Administration interspace, n (%)			0.941 <sup>§§§</sup>
L2–3	5 (9.4%)	29 (9.9%)	
L3–4	45 (84.9%)	243 (83.2%)	
L4–5	3 (5.7%)	20 (6.8%)	


*T* thoracic vertebrae, *L* lumbar vertebrae

<sup>§</sup>Mann–Whitney *U* test

<sup>§§§</sup> $\chi^2$  test



**Fig. 4** Pearson correlation between  $\Delta BP_{\text{mean}}$  and BMI.  $\Delta BP_{\text{mean}}$  Drop of mean blood pressure, BMI Body Mass Index



**Fig. 5** Pearson correlation between  $\Delta BP_{\text{mean}}$  and baseline  $BP_{\text{mean}}$ .  $\Delta BP_{\text{mean}}$  drop of mean blood pressure, baseline  $BP_{\text{mean}}$  baseline mean blood pressure

sensory block spread may be a risk factor for bradycardia. It seems that patients with a sympathetic block spread up to T2–4 had a higher incidence of bradycardia than patients with a block up to T5–6.

Regarding potential risk factors for SAIH, BMI was related to a pronounced drop of  $BP_{\text{mean}} > 25\%$  in our study, which confirms previous findings [40]. Esposito et al. observed that obese women have a higher sympathetic activity with a higher 24-h BP profile [41]. It may be hypothesized that patients with a higher sympathetic activity are susceptible to a more pronounced drop in BP due to SpA-induced sympatholysis.

Our findings of an association of higher baseline  $BP_{\text{mean}}$  with a drop of  $BP_{\text{mean}} > 25\%$  was supported by a retrospective analysis of 919 patient data receiving epidural or SpA for elective C/S [42]. The authors identified the higher baseline  $BP_{\text{mean}}$  and maternal hypertension to be among other maternal risk factors that could influence a greater drop of  $BP_{\text{mean}}$  after induction of neuraxial anaesthesia.

## Limitations

Our study used a historic control group that prospectively collected data, but nevertheless carried the risk of investigator and selection bias. Furthermore, a blinding of the study personnel was not feasible in the setting of a historic control group comparison. Another limitation is the significant difference in baseline  $BP_{\text{mean}}$  of the crystalloid and colloid groups. Interestingly, the seemingly clinically negligible difference of only 3 mmHg  $BP_{\text{mean}}$  may have had an impact on the significant correlation between baseline  $BP_{\text{mean}}$  and  $\Delta BP_{\text{mean}}$ . To be sure of the impact of this difference, a prospective randomized and blinded trial accounting for these confounders would be needed to confirm our results.

## Conclusion

From our findings we conclude that despite the greater incidence of SAIH and a greater drop in  $BP_{\text{mean}}$  in patients receiving a coload of crystalloid vs. colloid in conjunction with vasopressors, coload with a crystalloid is a safe strategy for the management of SAIH. This strategy was associated with no difference in outcome for the mother or newborn as measured by umbilical pH and APGAR scores.

**Acknowledgements** The Editors would like to acknowledge the help of Geoffrey Reading and Andreas Bietenbeck who have given their expertise and time in reviewing the manuscript.

**Funding** None.

## Compliance with ethical standards

**Conflict of interest** The authors declare no competing financial interest.

## References

1. Tawfik MM, Hayes SM, Jacoub FY, Badran BA, Gohar FM, Shabana AM, Abdelkhalek M, Emar MM. Comparison between colloid preload and crystalloid co-load in cesarean section under spinal anesthesia: a randomized controlled trial. *Int J Obstet Anesth.* 2014;23(4):317–23.

2. Marcus HE, Behrend A, Schier R, Dagtekin O, Teschendorf P, Böttiger BW, Spöhr F. Anästhesiologisches Management der Sectio caesarea: Deutschlandweite Umfrage. *Anaesthesist*. 2011;60(10):916–28.
3. Ripollés Melchor J, Espinosa, Martínez Hurtado E, Casans Francés R, Navarro Pérez R, Abad Gurumeta A, Calvo Vecino JM. Colloids versus crystalloids in the prevention of hypotension induced by spinal anesthesia in elective cesarean section. A systematic review and meta-analysis. *Miner Anesthesiol*. 2015;81:1019–30.
4. Kinsella SM, Carvalho B, Dyer RA, Fernando R, McDonnell N, Mercier FJ, Palanisamy A, Sia ATH, Van de Velde M, Vercueil A, Consensus Statement Collaborators. International consensus statement on the management of hypotension with vasopressors during caesarean section under spinal anaesthesia. *Anaesthesia*. 2018;73(1):71–92.
5. Reynolds F, Seed PT. Anaesthesia for Caesarean section and neonatal acid–base status: a meta-analysis. *Anaesthesia*. 2005;60(7):636–53.
6. Cyna AM, Andrew M, Emmett RS, Middleton P, Simmons SW. Techniques for preventing hypotension during spinal anaesthesia for caesarean section. *Cochrane Database Syst Rev*. 2006;4(4):CD002251.
7. Klöhr S, Roth R, Hofmann T, Rossaint R, Heesen M. Definitions of hypotension after spinal anaesthesia for caesarean section: literature search and application to parturients. *Acta Anaesthesiol Scand*. 2010;54(8):909–21.
8. Sharwood-Smith G, Drummond GB. Hypotension in obstetric spinal anaesthesia: a lesson from pre-eclampsia. *Br J Anaesth*. 2009;102(3):291–4.
9. Lee JE, George RB, Habib AS. Spinal-induced hypotension: Incidence, mechanisms, prophylaxis, and management: summarizing 20 years of research. *Best Pract Res Clin Anaesthesiol*. 2017;31(1):57–68.
10. Nag DS, Samaddar DP, Chatterjee A, Kumar H, Dembla A. Vasopressors in obstetric anesthesia: a current perspective. *World J Clin Cases*. 2015;3(1):58–64.
11. Gogarten W. Spinal anaesthesia for obstetrics. Vol. 17, best practice and research. *Clin Anaesthesiol*. 2003. 2013:377–92.
12. Lirk P, Haller I, Wong C. a. Management of spinal anaesthesia-induced hypotension for caesarean delivery: a European survey. *Eur J Anaesthesiol*. 2012;29(9):452–3.
13. Mercier FJ. Fluid loading for cesarean delivery under spinal anesthesia: have we studied all the options? *Anesth Analg*. 2011;113(4):677–80.
14. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. *Intensive Care Med*. 2013. 39:558–68.
15. Hunsicker O, Francis RC. Comment on: Assessment of hemodynamic efficacy and safety of 6% hydroxyethyl starch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: how to guide fluid therapy? *Crit Care (Lond, Engl)*. 2012;16:464.
16. Professional H. Hydroxyethyl starch solutions: FDA safety communication—boxed warning on increased mortality and severe renal injury and risk of bleeding. 2013.
17. European Medicines Agency. Hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients—CMDh endorses PRAC recommendations HES will be available in restricted patient populations. *Ema/640658/2013*. 2013;44(October):1–3.
18. Mercier FJ, Diemunsch P, Ducloy-Bouthors AS, Mignon A, Fischler M, Malinovsky JM, Bolandard F, Aya AG, Raucoules-Aimé M, Chassard D, Keita H, Rigouzzo A, Le Gouez A; CAESAR Working Group. 6% Hydroxyethyl starch (130/0.4) vs Ringer's lactate preloading before spinal anaesthesia for Caesarean delivery: the randomized, double-blind, multicentre CAESAR trial. *Br J Anaesth*. 2014;113(3):459–67.
19. Mercier FJ. Cesarean delivery fluid management. *Curr Opin Anaesthesiol*. 2012;25(3):286–91.
20. Kaufner L, Heimann S, Zander D, Weizsäcker K, Correns I, Sander M, Spies C, Schuster M, Feldheiser A, Henkelmann A, Wernecke KD, VON Heymann C. Neuraxial anesthesia for pain control after cesarean section: a prospective randomized trial comparing three different neuraxial techniques in clinical practice. *Miner Anesthesiol*. 2016;82(5):514–24.
21. McDonald S, Fernando R, Ashpole K, Columb M. Maternal cardiac output changes after crystalloid or colloid coload following spinal anesthesia for elective cesarean delivery: a randomized controlled trial. *Anesth Analg*. 2011;113(4):803–10.
22. Arora P, Singh RM, Kundra S, Gautam PL. Fluid administration before caesarean delivery: does type and timing matter? *J Clin Diagn Res*. 2015;9(6):UC01–4.
23. Alimian M, Mohseni M, Safaeian R, Faiz SHR, Majedi MA. Comparison of hydroxyethyl starch 6% and crystalloids for preloading in elective caesarean section under spinal anaesthesia. *Med Arch (Sarajevo Bosnia Herzegovina)*. 2014;68(4):279–81.
24. Oh A-Y, Hwang J-W, Song I-A, Kim M-H, Ryu J-H, Park H-P, Jeon Y-T, Do S-H. Influence of the timing of administration of crystalloid on maternal hypotension during spinal anesthesia for cesarean delivery: preload versus coload. *BMC Anesthesiol*. 2014;14(1):36.
25. Ueyama H, He YL, Tanigami H, Mashimo T, Yoshiya I. Effects of crystalloid and colloid preload on blood volume in the parturient undergoing spinal anesthesia for elective Cesarean section. *Anesthesiology*. 1999;91(6):1571–6.
26. Ewaldsson CA, Hahn RG. Volume kinetics of Ringer's solution during induction of spinal and general anaesthesia. *Br J Anaesth*. 2001;87(3):406–14.
27. Ngan Kee WD. The use of vasopressors during spinal anaesthesia for caesarean section. *Curr Opin Anaesthesiol*. 2017;30(3):319–25.
28. Habib AS. A review of the impact of phenylephrine administration on maternal hemodynamics and maternal and neonatal outcomes in women undergoing cesarean delivery under spinal anesthesia. *Anesth Analg*. 2012;114(2):377–90.
29. Ngan Kee WD, Khaw KS, Ng FF, Lee BB. Prophylactic phenylephrine infusion for preventing hypotension during spinal anesthesia for cesarean delivery. *Anesth Analg*. 2004;815–21.
30. Erler I, Gogarten W. Geburtshilfliche anästhesie: hypotonieprophylaxe und -therapie bei regionalanästhesien zur sectio caesarea. *Anesthesiol Intensivmed Notfallmedizin Schmerztherapie*. 2007;42(3):208–13.
31. Ngan Kee WD, Tam YH, Khaw KS, Ng FF, Lee SWY. Closed-loop feedback computer-controlled phenylephrine for maintenance of blood pressure during spinal anesthesia for cesarean delivery: a randomized trial comparing automated boluses versus infusion. *Anesth Analg*. 2017;125(1):117–23.
32. Heller AR, Heger J, Gama de Abreu M, Müller MP. Cafedrine/theodrenaline in anaesthesia. *Anaesthesist*. 2015;64(3):190–6.
33. Bein B, Christ T, Eberhart LHJ. Cafedrine/theodrenaline (20:1) is an established alternative for the management of arterial hypotension in Germany—a review based on a systematic literature search. *Front Pharmacol*. 2017;8(FEB):1–8.
34. Gogarten W, Aken H, Van Kessler P, Wulf H. Durchführung von Analgesie- und Anästhesieverfahren in der Geburtshilfe. *Anästhesiol Intensivmed*. 2009;50:183–90.
35. Clemens KE, Quednau I, Heller AR, Klaschik E. Impact of cafedrine/theodrenaline (Akrinor(R)) on therapy of maternal hypotension during spinal anesthesia for Cesarean delivery: a retrospective study. *Miner Gynecol*. 2010;62(6):515–24.

36. Strümper D, Gogarten W, Durieux ME, Hartleb K, Van Aken H, Marcus MAE. Effects of cafedrine/theodrenaline, etilefrine and ephedrine on uterine blood flow during epidural-induced hypotension in pregnant sheep. *Fetal Diagn Ther.* 2005;20(5):377–82.
37. Crystal GJ, Salem MR. The Bainbridge and the “reverse” Bainbridge reflexes: history, physiology, and clinical relevance. *Anesth Analg.* 2012;114:520–32.
38. Kyokong O, Charuluxananan S, Sriprajittichai P, Poomseetong T, Naksin P. The incidence and risk factors of hypotension and bradycardia associated with spinal anesthesia. *J Med Assoc Thai.* 2006;89:Suppl 3.
39. Somboonviboon W, Kyokong O, Charuluxananan S, Narasethakamol A. Incidence and risk factors of hypotension and bradycardia after spinal anesthesia for cesarean section. *J Med Assoc Thai.* 2008;91(2):181–7.
40. Brenck F, Hartmann B, Katzer C, Obaid R, Bruggmann D, Benson M, Röhrig R, Junger A. Hypotension after spinal anesthesia for cesarean section: identification of risk factors using an anesthesia information management system. *J Clin Monit Comput.* 2009;23(2):85–92.
41. Esposito K, Marfella R, Gualdiro P, Carusone C, Pontillo A, Giugliano G, Nicoletti G, Giugliano D. Sympathovagal balance, nighttime blood pressure, and QT intervals in normotensive obese women. *Obes Res.* 2003;11(5):653–9.
42. Maayan-Metzger A, Schushan-Eisen I, Todris L, Etchin A, Kuint J. Maternal hypotension during elective cesarean section and short-term neonatal outcome. *Am J Obstet Gynecol.* 2010;202:1.

## Affiliations

Lutz Kaufner<sup>1</sup> · A. Karekla<sup>2</sup> · A. Henkelmann<sup>1</sup> · S. Welfle<sup>2</sup> · K. von Weizsäcker<sup>3</sup> · L. Hellmeyer<sup>4</sup> · C. von Heymann<sup>1,2</sup>

<sup>1</sup> Department of Anaesthesiology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany

<sup>2</sup> Department of Anaesthesiology, Intensive Care Medicine, Emergency Medicine and Pain Therapy, Vivantes Klinikum im Friedrichshain, Berlin, Germany

<sup>3</sup> Department of Obstetrics, Charité-Universitätsmedizin Berlin, Berlin, Germany

<sup>4</sup> Department of Obstetrics and Gynaecology, Vivantes Klinikum im Friedrichshain, Berlin, Germany